SFA-002: A Novel Oral Drug for Treating Autoimmune Disease: Results in Psoriasis
Time: 11:30 am
day: Day Two AM
Details:
- Outlining SFA-002 mechanism of action by immunomodulation over immunosuppression
- Preclinical, phase Ia and phase Ib efficacy findings
- Safety profile
- Durable responses
- Special populations – scalp/palmoplantar psoriasis cohorts
- Differentiation strategy: convenience, cost, and multi-pathway modulation
